Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Onconetix, Inc. reported Q1 2026 progress at its Swiss subsidiary Proteomedix AG, highlighting two new peer-reviewed publications confirming the clinical utility of Proclarix, a diagnostic test to better identify clinically significant prostate cancer and reduce unnecessary biopsies. The company also launched the PRIME multi-center clinical validat…